MRNA Stock Rises 3% in Pre-Market, Moderna Vaccine Study Reveals Positive Immune Response
Moderna (MRNA) stock has positively reacted to the news about good results shown by the company’s COVID-19 vaccine candidate.
Moderna (MRNA) Stock Below $70 Again, Why It Jumped and Then Plunged?
The Moderna episode is a case study of how the coronavirus pandemic and the desperate hunt for treatments and vaccines are shaking up the financial markets. Now Moderna (MRNA) stock is trading below $70 again.
Moderna (MRNA) Stock Skyrocketed Over 19% Today After First Human Vaccine Testing
Moderna (MRNA) stock rocketed today after the biotech company dosed the first patient in a study of its coronavirus vaccine. The drug aims to use a natural function called messenger RNA to protect against the SARS-CoV-2 virus that causes Covid-19.